Charterhouse has agreed to acquire French pharmaceutical business, Cooper, from investment company Caravelle
October 15, 2015
Charterhouse Capital Partners (“Charterhouse”) today announces it has closed the acquisition of Coopération Pharmaceutique Française, the French pharmaceuticals distributor known as Cooper, alongside the incumbent management team from investment fund, Caravelle. This is the first acquisition from our tenth-generation fund, Charterhouse Capital Partners X.
Cooper is a leading independent French OTC drug manufacturer and distributor. It operates a distinctive business model with a unique distribution network and best-in-class sales force accessing all 22,000 pharmacies across France. Cooper has a diversified product portfolio with the top 20 product families benefitting from strong brand awareness. Cooper is headquartered in France with approximately 490 full time employees.
Charterhouse Capital Partners X is a 2016 vintage €2.3bn fund investing in high-quality mid-market European businesses across the services, healthcare, industrial and consumer sectors.
Share this news on